Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.

Press MF, Gordon MA, Slamon DJ.

J Clin Oncol. 2012 Feb 1;30(4):357-61. doi: 10.1200/JCO.2011.35.1023. Epub 2011 Dec 27. No abstract available.

2.

Multifactorial approach to predicting resistance to anthracyclines.

Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C.

J Clin Oncol. 2011 Apr 20;29(12):1578-86. doi: 10.1200/JCO.2010.31.2231. Epub 2011 Mar 21.

PMID:
21422418
3.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.

4.

[Current status of epirubicin in the treatment of breast neoplasm].

Jiang ZF, Song SC.

Zhonghua Zhong Liu Za Zhi. 2005 Apr;27(4):193-5. Chinese. No abstract available.

PMID:
15949413
5.

Epirubicin approved for breast cancer treatment.

Miller JL.

Am J Health Syst Pharm. 1999 Nov 1;56(21):2177. No abstract available.

PMID:
10565690
6.

Epirubicin in breast cancer: present and future.

Levine M.

Clin Breast Cancer. 2000 Sep;1 Suppl 1:S62-7. Review.

PMID:
11970752
7.

Epirubicin as adjuvant therapy for breast cancer.

Suh C.

Cancer Pract. 2001 Mar-Apr;9(2):104-6. No abstract available.

PMID:
11879287
8.

Epirubicin as adjuvant therapy in breast cancer.

Earl H, Iddawela M.

Expert Rev Anticancer Ther. 2004 Apr;4(2):189-95. Review.

PMID:
15056049
9.

Epirubicin hydrochloride.

Dolbey C.

Clin J Oncol Nurs. 2002 Jul-Aug;6(4):247-8. No abstract available.

PMID:
12087624
10.

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.

11.

Epirubicin for adjuvant therapy in node-positive breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2000 Feb 7;42(1071):12-3. No abstract available.

PMID:
10725968
12.

[Polychemotherapy versus monotherapy in metastatic breast carcinoma].

Tanner J, Dunst J.

Strahlenther Onkol. 1999 Sep;175(9):471. German. No abstract available.

PMID:
10518983
13.

Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.

Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfield S, Hill W, Kates R.

Clin Cancer Res. 1998 Jun;4(6):1451-7.

14.

[Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].

Biskup P, Wozakowska-Kapłon B, Góźdź S.

Pol Arch Med Wewn. 2006 Jun;115(6):551-8. Polish. No abstract available.

PMID:
17263227
15.
16.

Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2009 Jun 15;15(12):4234-41. doi: 10.1158/1078-0432.CCR-08-1479. Epub 2009 Jun 9.

17.

Role of epirubicin in advanced breast cancer.

Conte PF, Gennari A, Landucci E, Orlandini C.

Clin Breast Cancer. 2000 Sep;1 Suppl 1:S46-51. Review.

PMID:
11970749
18.
20.

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.

Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC.

Breast Cancer Res Treat. 2010 Aug;123(1):189-96. doi: 10.1007/s10549-010-0983-z. Epub 2010 Jun 26.

PMID:
20582464

Supplemental Content

Support Center